A significant rise in chronic chikungunya cases in Mumbai and Pune is raising concerns among health experts, with approximately 20-30% of patients experiencing lingering symptoms beyond six weeks.
The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...